Stocks and Investing
Stocks and Investing
Wed, August 9, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Renza Maintained (ADCT) at Buy with Decreased Target to $9 on, Aug 9th, 2023
Gregory Renza of RBC Capital, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $10 to $9 on, Aug 9th, 2023.
Gregory has made no other calls on ADCT in the last 4 months.
There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jeffrey Hung of "Morgan Stanley" Reiterated at Hold and Held Target at $5 on, Tuesday, July 11th, 2023
These are the ratings of the 2 analyists that currently disagree with Gregory
- Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $12 on, Tuesday, July 25th, 2023
- Tazeen Ahmad of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $2 on, Monday, April 24th, 2023
Contributing Sources